Diabetic retinopathy (DR) causes significant visual loss on a global scale. Treatments for the
vision-threatening complications of diabetic macular edema (DME) and proliferative diabetic …

Diabetic retinopathy diagnostic assessment and treatment options have improved
dramatically since the 2002 American Diabetes Association Position Statement (1). These …

Diabetes mellitus (DM) is a global epidemic and affects populations in both developing and
developed countries, with differing health care and resource levels. Diabetic retinopathy …

OBJECTIVE: Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with
focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema …

Background The relative efficacy and safety of intravitreous aflibercept, bevacizumab, and
ranibizumab in the treatment of diabetic macular edema are unknown. Methods At 89 …

Comprising more than 61,000 servers located across nearly 1,000 networks in 70 countries
worldwide, the Akamai platform delivers hundreds of billions of Internet interactions daily …

Objective To report expanded 2-year follow-up of a previously reported randomized trial
evaluating intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with focal/grid …

Background To reduce treatment burden and optimise patient outcomes in diabetic macular
oedema, we present 1-year results from two phase 3 trials of faricimab, a novel angiopoietin …

OBJECTIVE To evaluate the extent of pancreatic β-cell function in a large number of insulin-
dependent diabetic patients with a disease duration of 50 years or longer (Medalists) …

Importance Panretinal photocoagulation (PRP) is the standard treatment for reducing severe
visual loss from proliferative diabetic retinopathy. However, PRP can damage the retina …